Cargando…

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Detalles Bibliográficos
Autor principal:	Deel, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226313/ https://www.ncbi.nlm.nih.gov/pubmed/28090370

Ejemplares similares

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
por: Lim, Joline S. J., et al.
Publicado: (2016)

Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer
por: Dermarkarian, Christopher R., et al.
Publicado: (2020)

Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
por: Ansari, Jawaher, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago, Giulia, et al.
Publicado: (2016)

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
por: Săftescu, Sorin, et al.
Publicado: (2021)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
por: Le, Alexander D, et al.
Publicado: (2017)

Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer
por: Ladwa, Rahul, et al.
Publicado: (2020)

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
por: Hida, Toyoaki
Publicado: (2018)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors
por: Baseri, Babak, et al.
Publicado: (2019)

Successful continuous nivolumab therapy for metastatic non‐small cell lung cancer after local treatment of oligometastatic lesions
por: Tobita, Satoshi, et al.
Publicado: (2020)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo, Geng-wei, et al.
Publicado: (2021)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
por: Reuss, Joshua E, et al.
Publicado: (2020)

Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
por: Takada, Kenji, et al.
Publicado: (2021)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma
por: Singh, Navdeep, et al.
Publicado: (2020)

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer
por: Britschgi, Christian, et al.
Publicado: (2018)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018)

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019)

Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
por: Feld, Emily, et al.
Publicado: (2017)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
por: Botticelli, Andrea, et al.
Publicado: (2019)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
por: Higuchi, Mitsunori, et al.
Publicado: (2016)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
por: Sata, Masafumi, et al.
Publicado: (2021)

Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer
por: Kosche, Cory, et al.
Publicado: (2018)

“Lazarus response” of nivolumab in a frail patient with non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2017)

Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
por: Ota, Takahiro, et al.
Publicado: (2019)

A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
por: Chen, Shuo, et al.
Publicado: (2018)

Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
por: Mori, Hidenori, et al.
Publicado: (2019)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Karaboué, Abdoulaye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8nhb7um31l3jku0q8e9g58emof